Mesentech Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 19

Mesentech General Information

Description

Developer of prostaglandin prodrugs designed to support musculoskeletal regeneration. The company's drug conjugates target mesenchymal stem cells with a potent sub-nano-molar prostaglandin mimetic that is released selectively in the bone, resulting in bone regeneration, enabling hospitals to treat low-bone-density disorders and hopes to rescue non-unions from surgical revision and accelerate bone healing.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2222 Health Sciences Mall
  • Vancouver, British Columbia V6T 1Z3
  • Canada
+1 (774)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Corporate Office
  • 2222 Health Sciences Mall
  • Vancouver, British Columbia V6T 1Z3
  • Canada
+1 (774)

Mesentech Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mesentech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 01-Nov-2024 Completed Clinical Trials - Phase 1
9. Later Stage VC 04-Oct-2023 Completed Clinical Trials - Phase 1
8. Early Stage VC 13-Apr-2022 Completed Clinical Trials - Phase 1
7. Accelerator/Incubator 04-Dec-2020 Completed Clinical Trials - Phase 1
6. Early Stage VC 02-Nov-2020 Completed Clinical Trials - Phase 1
5. Early Stage VC 24-May-2019 Completed Clinical Trials - Phase 1
4. Accelerator/Incubator 07-May-2019 Completed Clinical Trials - Phase 1
3. Early Stage VC 01-Dec-2018 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 01-Dec-2018 Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 01-Jan-2018 Completed Startup
To view Mesentech’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Mesentech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of prostaglandin prodrugs designed to support musculoskeletal regeneration. The company's drug conjugates targ
Drug Discovery
Vancouver, Canada
11 As of 2025

New Haven, CT
 

Westlake Village, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mesentech Competitors (4)

One of Mesentech’s 4 competitors is IRulya Therapeutics, a Formerly VC-backed company based in New Haven, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
IRulya Therapeutics Formerly VC-backed New Haven, CT
Angitia Biopharmaceuticals Venture Capital-Backed Westlake Village, CA
Amgen Formerly PE-Backed Thousand Oaks, CA
Ultragenyx Pharmaceutical Formerly VC-backed Novato, CA
To view Mesentech’s complete competitors history, request access »

Mesentech Patents

Mesentech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026013441-A1 Bisphosphonate-ep4 agonists for selective delivery to damaged muscle Pending 10-Jul-2024

Mesentech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mesentech Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
7G Bioventures Venture Capital Minority
Boutique Venture Partners Venture Capital Minority
Charles H. Hood Foundation Limited Partner Minority
CureDuchenne Ventures Corporate Venture Capital Minority
Morningside Group Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Mesentech FAQs

  • When was Mesentech founded?

    Mesentech was founded in 2018.

  • Where is Mesentech headquartered?

    Mesentech is headquartered in Vancouver, Canada.

  • What is the size of Mesentech?

    Mesentech has 11 total employees.

  • What industry is Mesentech in?

    Mesentech’s primary industry is Drug Discovery.

  • Is Mesentech a private or public company?

    Mesentech is a Private company.

  • What is Mesentech’s current revenue?

    The current revenue for Mesentech is .

  • How much funding has Mesentech raised over time?

    Mesentech has raised $27.5M.

  • Who are Mesentech’s investors?

    7G Bioventures, Boutique Venture Partners, Charles H. Hood Foundation, CureDuchenne Ventures, and Morningside Group are 5 of 19 investors who have invested in Mesentech.

  • Who are Mesentech’s competitors?

    IRulya Therapeutics, Angitia Biopharmaceuticals, Amgen, and Ultragenyx Pharmaceutical are competitors of Mesentech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process